Researchers developed a directed evolution method to create peptide mimotopes that, when delivered as a vaccine-like booster, restimulate CAR-T cells in vivo and improve their ability to fight blood cancers in mice.
Generalizable to any CAR-T productThe directed evolution platform can generate peptide boosters for any chimeric antigen receptor, not just CD19-targeting products
What the researchers found
Using yeast surface display and directed evolution, the team identified and optimized peptide mimotopes that bind to FMC63 — the antibody fragment used in clinical CD19 CAR-T products. These peptides were coupled to a lymph node-targeting amphiphilic PEG-lipid carrier (amph-vax) to create a vaccine-like booster.
In both syngeneic and humanized mouse models of B-acute lymphoblastic leukemia/lymphoma, the optimized amph-vax boosters triggered marked expansion and memory development of CD19 CAR-T cells. Mice receiving the peptide vaccine booster showed enhanced control of disease progression compared to those treated with CAR-T cells alone. The approach is designed to be generalizable to any CAR-T cell product.
Why it matters
CAR-T cell therapy has transformed treatment for certain blood cancers, but relapse remains a major challenge — often because the engineered T cells lose steam. A simple peptide-based vaccine booster that can be given after CAR-T infusion to recharge these cells could dramatically improve long-term outcomes. Importantly, this approach is designed to work with any CAR-T product, not just one specific therapy.
How the study worked
The researchers used yeast surface display — a technique where billions of peptide variants are displayed on yeast cells — to screen for peptides that bind to the FMC63 antibody fragment used in approved CD19 CAR-T products. The best candidates were then further improved through directed evolution (iterative rounds of mutation and selection). The optimized peptides were linked to an amphiphilic PEG-lipid carrier that targets lymph nodes. Efficacy was tested in syngeneic and humanized mouse models of B-ALL/lymphoma.
What this study cannot tell us
All efficacy data comes from mouse models (syngeneic and humanized), which do not fully replicate the human immune environment or tumor complexity. The study focused on CD19-targeting CARs; while the authors state the approach is generalizable, this has not yet been demonstrated for other CAR targets. No human clinical data is available yet. The long-term durability of the boosting effect and potential for immune-related side effects need further study.
How to read the evidence
This is a preclinical study published in a top-tier journal (Nature Biomedical Engineering) using both syngeneic and humanized mouse models, representing strong preclinical evidence. However, no human data exists yet, so the clinical relevance remains to be confirmed.
When this study was published
Published in 2025, this is a cutting-edge study at the forefront of CAR-T cell booster technology.
The bigger picture
CAR-T cell persistence is one of the biggest unsolved problems in cancer immunotherapy. This work addresses it from a novel angle: rather than re-engineering the T cells themselves, it uses peptide-based vaccines to boost them after they're already in the patient. Published in Nature Biomedical Engineering, this represents a potentially transformative approach that could be combined with any existing or future CAR-T product.
Questions still open
- Will the peptide vaccine booster be safe and effective in human patients, and could it cause cytokine release syndrome or other immune side effects?
- Can this directed evolution approach successfully generate mimotopes for CAR-T products targeting antigens other than CD19?
- How many booster doses would be optimal, and how long does the CAR-T restimulation effect last?
Common questions
Why do CAR-T cells stop working, and how does this vaccine help?
What is directed evolution and why was it used here?
Read the original research
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.
Nature biomedical engineering
Citation
Grzywa, Tomasz M; Neeser, Alexandra; Ramasubramanian, Ranjani; Romanov, Anna; Tannir, Ryan; Mehta, Naveen K; Cossette, Benjamin; Morgan, Duncan M; Goncalves, Beatriz; Sukaj, Ina; Bergaggio, Elisa; Kadauke, Stephan; Myers, Regina M; Paruzzo, Luca; Ghilardi, Guido; Cozzone, Austin; Schuster, Stephen J; Frey, Noelle; Zhang, Libin; Yousefpour, Parisa; Abraham, Wuhbet; Suh, Heikyung; Ruella, Marco; Grupp, Stephan A; Chiarle, Roberto; Wittrup, K Dane; Ma, Leyuan; Irvine, Darrell J. (2025). Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.. Nature biomedical engineering. https://doi.org/10.1038/s41551-025-01470-0